Diabetes UK 2023 Resource Hub –
Welcome to our resource hub for Diabetes UK Professional Conference 2023! This is a one-stop-shop for all your Diabetes UK needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Useful Conference Links
Day-of Conference Reports
Diabetes Therapy Highlights
- Professor Naveed Sattar delivers exceptional Banting Memorial Lecture, underscoring urgency of weight management for healthcare systems
- AstraZeneca symposium focuses on Forxiga (dapagliflozin) for primary prevention and treatment of CKD
- Genetic risk may set the scene, but one’s environment drives disease and risk: Cambridge’s Dr. Nick Wareham underscores how type 2 diabetes is a public health manifestation of a societal problem
- NHS’s Type 2 Diabetes Path to Remission program associated with 10% weight loss after one year; over 7,000 referrals to date
- NewDAWN research program aims to develop new NHS service offering range of weight loss diets for people with overweight, obesity, and/or newly diagnosed T2D
- Professor Samina Ali offers a pharmacist perspective on newer drugs and therapeutic approaches
- UK is bullish on teplizumab, but cost remains barrier for clinical adoption; verapamil mentioned, only two months after CLVer readout
Diabetes Technology Highlights
- Preliminary Dexcom ONE data from UK (n=43) shows 1.8% A1c reduction from baseline of 10.0% at six months; NICE pays same (or less) for Dexcom ONE vs. is-CGM
- NHS England’s Jonathan Valabhji and Partha Kar discuss greater focus on weight management and CGM; NHS has spent £400 million on diabetes tech over last five years
- Professor Sam Seidu positions CGM as a means to avoid long-term complications and sees room for use in non-insulin-treated T2D
- Abbott-sponsored session features Dr. Emma Wilmot riffing on NICE coverage for CGM in T2D, as well as the future of AID for T1D in the UK
- NHS’ type 1 diabetes hybrid closed loop pilot (n=520): Adjusted A1c reduction of 1.7% at six months, down to 7.8%; Time in Range improves 6.7 hours/day to 63%
- myLife Loop AID system with Libre 3 available in UK; a look at three-year Libre audit data, as well as Time in Tight Range outcomes (70-140 mg/dL) from iLet and Control-IQ pivotals, CREATE RCT, and SURPASS-3 CGM
Diabetes Big Picture Highlights
- DiRECT Extension results: Diet-induced weight loss with ongoing support can lead to type 2 diabetes remission for up to five years
- Professor Roy Taylor argues that ReTUNE results support notion of personal fat threshold; at one year, 70% (n=20) achieved remission of T2D
- ABCD will run glucose monitoring audit in 2023 with focus on type 2 diabetes, including Dexcom ONE rt-CGM audit; ABCD DTN-UK hybrid closed loop pilot results will be presented later at DUK
- The role of epigenetics in predicting, preventing, and treating diabetes; could DNA methylation be a therapeutic target in the future?
- Genetic factors, not genetic determinants: Dr. Inês Barroso delivers exceptional opening lecture on genetics of type 2 diabetes with a focus on clinical translation
- Type 1 Diabetes Grand Challenge: £50 million toward treatments and cure of T1D; largest donation for diabetes research in UK
- Professor Martin Rutter riffs on the importance of epidemiology to diabetes during RD Lawrence Lecture
- The genetic underpinnings of the human diet: ADA-backed PREMIER study aims to assign polygenic scores to macronutrient preferences
- Patient-reported outcomes – it “isn’t difficult!” The growing momentum toward broader adoption of PROs in diabetes
- “Quality in Care” Winners: Deapp’s pediatric diabetes education, virtual reality-based clinical education, virtual diabetes care training for school staff, and mental health improvement for PWD with recurrent DKA
- UK audit reveals concerning treatment gap for people with early-onset type 2 diabetes; pregnancy T2D outcomes from Prof. Helen Murphy are further cause for concern
- Emerging fMRI research reveals differential brain activity in individuals following weight loss through diet vs. bariatric surgery
- “The care processes are still poor, the evidence base is still poor, and we need to up our game”: Professor Melanie Davies highlights urgency of early-onset T2D
- DIPLOMA is auditing NHS Diabetes Prevention Program; results point to cost-effectiveness, but contracted HCPs are not always delivering program correctly
- A “tricky fine line”: DKA remains a costly and dangerous complication of diabetes; euglycemic DKA accounts for 3% of DKA cases in UK